Efficacy of Crizotinib After Entrectinib Resistance Due to <i>MET</i> Polysomy in <i>ROS1</i>-Rearranged NSCLC: A Case Report.

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report.

Takakura, Toshiaki; Kanemura, Hiroaki; Sakai, Kazuko; Nishio, Kazuto; Nakagawa, Kazuhiko; Hayashi, Hidetoshi.

Afiliación

Takakura T; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
Kanemura H; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Sakai K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
Nishio K; Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
Nakagawa K; Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
Hayashi H; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

JTO Clin Res Rep ; 4(6): 100523, 2023 Jun.

Article en En | MEDLINE | ID: mdl-37287496